An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis
Open Access
- 1 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 26 (8), 2526-2532
- https://doi.org/10.1093/ndt/gfr247
Abstract
Background. The recent finding that phospholipase-A 2 -receptor antibodies (PLA 2 R-AB) may play a role in the development of primary membranous glomerulonephritis (MGN) offers the opportunity to measure a marker to help diagnose, classify and eventually monitor the course of patients with MGN. Methods. We developed an immunofluorescence test, which allows the easy and specific analysis of the presence of PLA 2 R-AB in serum. The usefulness of this test was studied in 153 healthy blood donors, 90 patients with non-membranous glomerular injuries, 17 patients with a secondary form of MGN and 100 patients with biopsy-proven primary MGN. In addition, in five patients with biopsy-proven MGN, PLA 2 R-AB levels were monitored prospectively for up to 18 months following a single dose of rituximab (RTX) (375 mg/m 2 body surface). Results. PLA 2 R-AB were not found in healthy controls or patients with glomerular lesions other than biopsy-proven primary MGN. Fifty-two patients with primary MGN (52%) were positive for PLA 2 R-AB. The levels ranged from 1:10 to 1:3200. In patients who had MGN and were treated with RTX the fall in PLA 2 R-AB levels was followed by a decrease in proteinuria, whereas an increase in PLA 2 R-AB levels was associated with an increase in proteinuria. Conclusions. These studies show that the new test allows the monitoring of PLA 2 R-AB levels in patients with MGN and may help in making therapeutic decisions for these patients.Keywords
This publication has 11 references indexed in Scilit:
- PLA2R Autoantibodies and PLA2R Glomerular Deposits in Membranous NephropathyNew England Journal of Medicine, 2011
- Rituximab Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2010
- PLA2R Autoantibodies and Recurrent Membranous Nephropathy after TransplantationNew England Journal of Medicine, 2010
- Spontaneous Remission of Nephrotic Syndrome in Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2010
- Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritisProceedings of the National Academy of Sciences, 2010
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- Successful Treatment of Membranous Glomerulonephritis with Rituximab in Calcineurin Inhibitor-Dependent PatientsClinical Journal of the American Society of Nephrology, 2009
- Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2007
- Management of Membranous NephropathyJournal of the American Society of Nephrology, 2005
- Membranous Glomerulonephritis and MalignancyAmerican Journal of Kidney Diseases, 1993